Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

Completed

Conditions studied: Depression, Anxiety

In brief

Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial. The financial burden of treatment failures in direct treatment costs, disability, decreased productivity, and missed work may in part derive from a mismatch between optimal, and actual, medications prescribed. The present one year retrospective study seeks to evaluate the indirect and direct healthcare costs for 96 patients with a DSM-IV-TR depressive or anxiety disorder, in relation to an interpretive reporting system designed to predict antidepressant responses based on DNA variations in cytochrome P450 genes (CYP2D6, CYP2C19, CYP1A2), the serotonin transporter gene (SLC6A4), and the serotonin 2A receptor (5HTR2A) genes.

Key facts

Study ID

NCT01632267

Run by

Assurex Health Inc.

People needed

104

Starts

2011-01-01

Expected to finish

2011-09-01

Last updated by the study team

2016-01-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Major Depressive Disorder
• Dysthymic Disorder
• Depressive Disorder NOS
• Obsessive Compulsive Disorder (OCD)
• Generalized Anxiety Disorder
• Panic Disorder
• Anxiety Disorder NOS
• Post-Traumatic Stress Disorder (PTSD)
• Social Phobia

You may not qualify if…

• Bipolar Disorder
• Schizophrenia
• Schizoaffective Disorder
• Previous pharmacogenomic testing

Where it is running

• Union Health Services — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.